Editas Medicine (EDIT) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$25.1 million.
- Editas Medicine's Net Income towards Common Stockholders rose 5957.9% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 613.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 5637.63% down from last year.
- Per Editas Medicine's latest filing, its Net Income towards Common Stockholders stood at -$25.1 million for Q3 2025, which was up 5957.9% from -$51.5 million recorded in Q2 2025.
- Editas Medicine's 5-year Net Income towards Common Stockholders high stood at -$18.9 million for Q4 2023, and its period low was -$75.7 million during Q1 2025.
- In the last 5 years, Editas Medicine's Net Income towards Common Stockholders had a median value of -$51.5 million in 2025 and averaged -$50.2 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 60007.67% in 2021, then skyrocketed by 6894.66% in 2023.
- Editas Medicine's Net Income towards Common Stockholders (Quarter) stood at -$41.4 million in 2021, then plummeted by 46.58% to -$60.7 million in 2022, then skyrocketed by 68.95% to -$18.9 million in 2023, then tumbled by 140.68% to -$45.4 million in 2024, then skyrocketed by 44.67% to -$25.1 million in 2025.
- Its Net Income towards Common Stockholders was -$25.1 million in Q3 2025, compared to -$51.5 million in Q2 2025 and -$75.7 million in Q1 2025.